BTK and mantle cell lymphoma: Patients with MCL, WM, and CLL/SLL can now be treated with zanubrutinib, a highly selective [117,118], irreversible second-generation BTK inhibitor [76] which was approved by the FDA in 2019 [119] (Table 1).